We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Ocugen Inc is a biotechnology business with stocks listed in the US. Ocugen shares (OCGN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$5.97 – a decrease of 1% over the previous week. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | US$0.285 - US$18.77 |
|---|---|
| 50-day moving average | US$8.4182 |
| 200-day moving average | US$8.1493 |
| Target price | US$8.88 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | US$-0.253 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $5.97
| 1 week (2021-12-01) | -1.00% |
|---|---|
| 3 months (2021-09-08) | -16.03% |
| 6 months (2021-06-08) | -41.12% |
| 1 year (2020-12-08) | 1,873.55% |
|---|---|
| 2 years (2019-12-06) | 1,355.74% |
| 3 years (2018-12-07) | -79.48% |
| 5 years (2016-12-08) | -94.79% |
| Operating margin TTM | 12148347% |
|---|---|
| Gross profit TTM | US$-5,099,160 |
| Return on assets TTM | -32.56% |
| Return on equity TTM | -72.19% |
| Profit margin | 0% |
| Book value | 0.538 |
| Market capitalisation | US$1.3 billion |
TTM: trailing 12 months
We're not expecting Ocugen to pay a dividend over the next 12 months.
Ocugen's shares were split on a 1:60 basis on 29 September 2019. So if you had owned 60 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ocugen shares – just the quantity. However, indirectly, the new 5900% higher share price could have impacted the market appetite for Ocugen shares which in turn could have impacted Ocugen's share price.
Over the last 12 months, Ocugen's shares have ranged in value from as little as US$0.285 up to US$18.77. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ocugen's is 4.324. This would suggest that Ocugen's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
From where the no-makeup makeup look meets the model off duty vibe, we've put together a range of no-fuss products you'll love.
Every man wanted her – 1 man dared to love her.
Manchester United are scrambling to stay in touch with the top 4 as they host Arsenal this week
From toys to socks to beauty items, these are the top 12-day advent calendars you can still enjoy in the lead up to Christmas.
Steps to owning and managing McDonald's shares from in Australia.
Reputation + Christmas parties: could it be the potential volcano erupting leaving rands, families and individuals to deal with the fallout?
Insurtech Flip has shaken up the insurance industry by launching the first on-demand injury cover in the country.
Everything we know about the Qualitas Limited IPO, plus information on how to buy in.
Everything we know about the WA1 Resources IPO, plus information on how to buy in.
